About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.
(C) 2024 MINKABU THE INFONOID, Inc.

SAPPORO CLINICAL LABORATORY INC.(9776) Financial Results

9776
TSE Standard
SAPPORO CLINICAL LABORATORY INC.
975
JPY
+4
(+0.41%)
Dec 23, 11:27 am JST
6.23
USD
Dec 22, 9:27 pm EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
Current Period Guidance
Annual
Result
Guidance History
Growth Rate
Profitability
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2021 17,502 1,142 1,188 793 231.9 23 May 14, 2021 J-GAAP
Mar, 2022 19,109 1,537 1,605 1,042 306.2 23 May 13, 2022 J-GAAP
Mar, 2023 20,127 1,008 1,159 568 170.5 23 May 12, 2023 J-GAAP
Mar, 2024 19,682 534 514 380 114.1 23 May 13, 2024 J-GAAP
Mar, 2025 Guidance 19,799 500 493 320 102.6 23 May 13, 2024 J-GAAP
YoY +0.6% -6.4% -4.1% -15.8% -10.1%
All-Time High
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 20,127 1,537 1,605 1,042 909.4
Fiscal Year Mar, 2023 Mar, 2022 Mar, 2022 Mar, 2022 Jun, 1993
Second Half
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2021 9,543 760 785 585 171.9 23 May 13, 2022 J-GAAP
Oct - Mar, 2022 10,163 516 570 310 93.1 23 May 12, 2023 J-GAAP
Oct - Mar, 2023 9,820 243 218 154 46.3 23 May 13, 2024 J-GAAP
Oct - Mar, 2024 Guidance 9,803 163 150 98 31.4 23 Nov 1, 2024 J-GAAP
YoY -0.2% -32.9% -31.2% -36.4% -32.1%
Cash Flow
Annual
Fiscal Year Operating Profit Fee Cash Flow Operating Cash Flow Investing Cash Flow Financial Cash Flow Cash & Equivalents Cash Ratio Accounting Standards
Mar, 2022 1,537 743 1,573 -830 -112 2,980 18.45 J-GAAP
Mar, 2023 1,008 1,021 1,430 -409 -347 3,654 22.12 J-GAAP
Mar, 2024 534 682 1,077 -395 -369 3,966 23.78 J-GAAP
Actual Performance and Financial Trends
Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2022 9,964 492 589 258 77.4 50.8 Nov 9, 2022 J-GAAP
Apr - Sep, 2023 9,862 291 296 226 67.9 57.6 Nov 10, 2023 J-GAAP
Apr - Sep, 2024 9,996 337 343 222 70.9 69.6 Nov 8, 2024 J-GAAP
YoY +1.4% +15.8% +15.9% -1.8% +4.3%
Quarterly Results
Result
Growth Rate
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Oct - Dec, 2022 5,286 324 382 235 70.5 6.1 Feb 10, 2023 J-GAAP
Jan - Mar, 2023 4,877 192 188 75 22.5 3.9 May 12, 2023 J-GAAP
Apr - Jun, 2023 4,922 75 80 5 1.7 1.5 Aug 7, 2023 J-GAAP
Jul - Sep, 2023 4,940 216 216 221 66.4 4.4 Nov 10, 2023 J-GAAP
Oct - Dec, 2023 4,990 123 121 85 25.6 2.5 Feb 9, 2024 J-GAAP
Jan - Mar, 2024 4,830 120 97 69 20.7 2.5 May 13, 2024 J-GAAP
Apr - Jun, 2024 4,999 98 102 56 17.9 2.0 Aug 5, 2024 J-GAAP
Jul - Sep, 2024 4,997 239 241 166 53.0 4.8 Nov 8, 2024 J-GAAP
YoY +1.2% +10.6% +11.6% -24.9% -20.2%
All-Time High Quarterly Results
Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS
Record 5,286 485 527 381 112.0
Fiscal Year Dec, 2022 Sep, 2021 Sep, 2021 Mar, 2022 Mar, 2022
Key Balance Sheet Figures
Fiscal Year BPS Equity Ratio Total Asset Equity Retained Earnings Interest-Bearing Debt Ratio Announce Accounting Standards
Mar, 2022 3,016.24 62.6 16,149 10,114 8,812 0.26 May 13, 2022 J-GAAP
Mar, 2023 3,178.25 64.1 16,521 10,585 9,304 0.23 May 12, 2023 J-GAAP
Mar, 2024 3,283.71 65.6 16,680 10,936 9,607 0.20 May 13, 2024 J-GAAP
Apr - Sep, 2024 3,486.29 66.3 16,408 10,876 9,753 0.19 Nov 8, 2024 J-GAAP